title: Response to bevacizumab after treatment with aflibercept in eyes with neovascular AMD.
abstract: OBJECTIVE
  To study the visual outcome and change in central macular thickness (CMT) in patients with neovascular age-related macular degeneration (AMD) who were previously treated with aflibercept (VEGF Trap-Eye, Eylea) and were subsequently switched to bevacizumab (Avastin).
  
  
  METHODS
  In this observational analysis, 19 eyes initially treated with at least 3 injections of bevacizumab after initial treatment with at least 3 injections of aflibercept are reported. Outcome measures were Snellen visual acuity (best-corrected visual acuity (BCVA) and CMT measured by spectral-domain optical coherence tomography.
  
  
  RESULTS
  A total of 19 eyes initially treated with 6.5 ± 2.8 intravitreal injections of aflibercept were switched to 5.4 ± 3.2 injections of bevacizumab. Median BCVA decreased from 20/94 to 20/113 after aflibercept and increased slightly to 20/101 after bevacizumab (p = 0.84, Friedman test). Of all 19 eyes, 36.8% achieved gain in visual acuity of more than 1 line and 21.1% of more than 3 lines. The CMT decreased slightly from 433 ± 229 μm at baseline to 367 ± 198 μm after aflibercept treatment (p = 0.18, Wilcoxon test) and decreased statistically significantly to 335 ± 184 μm after bevacizumab treatment (p = 0.0065, Wilcoxon test).
  
  
  CONCLUSIONS
  Switching from aflibercept to bevacizumab treatment has an equivalent anatomical effect in eyes with neovascular AMD as switching from bevacizumab to aflibercept. Therefore, switching back to bevacizumab might represent a reasonable therapy strategy to overcome tachyphylaxis during long-term monotherapy with aflibercept.
authors.affiliation: University Eye Hospital Basel, Centre for Ophthalmology, Basel - Switzerland.|Knappschaft Eye Clinic Sulzbach, Knappschaft Hospital Saar, Sulzbach/Saar - Germany.
authors.forename: Maria
authors.initials: M
authors.lastname: Waizel
authors.affiliation: Knappschaft Eye Clinic Sulzbach, Knappschaft Hospital Saar, Sulzbach/Saar - Germany.
authors.forename: Annekatrin
authors.initials: A
authors.lastname: Rickmann
authors.affiliation: University Eye Clinic Tuebingen, Centre for Ophthalmology, Tuebingen - Germany.
authors.forename: Björn R
authors.initials: BR
authors.lastname: Blanke
authors.affiliation: Knappschaft Eye Clinic Sulzbach, Knappschaft Hospital Saar, Sulzbach/Saar - Germany.
authors.forename: Katharina
authors.initials: K
authors.lastname: Wolf
authors.affiliation: University Eye Hospital Basel, Centre for Ophthalmology, Basel - Switzerland.|Knappschaft Eye Clinic Sulzbach, Knappschaft Hospital Saar, Sulzbach/Saar - Germany.
authors.forename: Sara
authors.initials: S
authors.lastname: Kazerounian
authors.affiliation: Knappschaft Eye Clinic Sulzbach, Knappschaft Hospital Saar, Sulzbach/Saar - Germany.|University Eye Clinic Tuebingen, Centre for Ophthalmology, Tuebingen - Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Szurman
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D057915:Drug Substitution; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor